Company: DVAX
Filing Date: 2025-05-12
Form Type: DEFA14A
Source: 0000930413-25-001704
Chunk: 29

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-05-12
Form: DEFA14A
Chunk 29
---
3 publicly - traded pharmaceutical companies, including Viridian Therapeutics, a biopharmaceutical company that engages in the development of proprietary RNA - targeted therapeutics x Proven track record of public company sales: Such as AMAG Pharmaceuticals, where he led the commercial stage company through its sale to Covis Pharma for $498M Selected Recent Public Company Experience ▪ Chairman of the Board | Zentalis Pharmaceuticals (Nasdaq: ZNTL) ▪ Former Chairman of the Board | Harpoon Therapeutics (Nasdaq: HARP) – Acquired by Merck for $680M ▪ Former CEO and President | Viridian Therapeutics (Nasdaq: VRDN) ▪ Former Independent Director | Selecta Biosciences (Nasdaq: SELB) ▪ Former Chairman of the Board | Sensorion SA (EPA: ALSEN) ▪ Former Independent Director | Trillium Therapeutics (Nasdaq/TSX: TRIL) – Acquired by Pfizer for $2.3B ▪ Former CEO | AMAG Pharmaceuticals (Nasdaq: AMAG) ▪ Former CEO & President | Cascadian Therapeutics (Nasdaq: CASC) – Acquired by Seattle Genetics for $614M ▪ Former Independent Director | Orexo AB (STO: ORX) Development, commercialization, executive and chairman experience are invaluable to Dynavax as we continue to develop and commercialize novel vaccines Brett Erkman Managing Director, Deep Track Capital No relevant biotech experience: Has never served as an executive at a biotech company or as a director of a public company No relevant operating experience: Has never served in an operational or financial role at any company Lacks the skillsets required to be an effective director on our board: Does not possess skills that would be additive to the current Board, including clinical development, commercial experience or vaccine R&D experience Misaligned interests: Position as a Deep Track principal may lead to a conflict of interest between Deep Track’s goals and directors’ duties to create long term value for all stockholders Public Biotech Executive Experience None Public Company Board Experience None vs © Copyright DYNAVAX 2025

ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx Unique perspective in drug development and commercialization and